BioSpace News Archive

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced preliminary, unaudited sales results for the second quarter ended June 30, 2021.

IRADIMED CORPORATION announced that the Company will release its 2021 second quarter financial results before the market opens on Friday, July 30th.

Reset Pharmaceuticals, Inc. today announced it has acquired an exclusive license from NYU Langone Health for intellectual property (IP) associated with the use of psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases, including cancer.

Aravive, Inc., a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, announced that Gail McIntyre, Ph.D., DBAT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the 2021 William Blair Biotech Focus Conference on July 15, 2021, at 3:00 PM ET.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced it has initiated a new study evaluating the physiologic impact of OLINVYK on respiratory function in elderly / obese subjects.

Bausch + Lomb and Novaliq GmbH announced the second of two Phase 3 studies evaluating the investigational drug NOV03 as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction, has been completely enrolled with a total of 622 participants.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced positive in vivo data demonstrating down-regulation of SNCA mRNA and protein-expression from a study of SLS-004 in an in-vivo rodent model utilizing CRISPR-dCas9 gene therapy technology.

Nevro Corp., a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on August 4, 2021.

Sema4 today announced the appointment of renowned executive Jason Ryan to its Board of Directors.

Augmedics, a pioneer in augmented reality surgical image guidance, announced the appointment of Rick Anderson as executive chairman of the board and Bradley Paddock as the board’s independent director.